Fulcrum to Merge with Slate Medicines in Pivot to Migraine Therapies
FULC sits 54% above its 52-week low of $2.83 on light trading volume (0.4× avg).
Summary
Fulcrum Therapeutics, a shell company after discontinuing its lead sickle cell program and cutting 85% of staff, has agreed to merge with Slate Medicines to advance next-generation migraine therapies. The all-stock merger values Slate at $350M and includes a $245M PIPE; pre-merger Fulcrum stockholders will own 5.0%, Slate stockholders 55.9%, and PIPE investors 39.1% of the combined company, whereas the base summary had stated Fulcrum stockholders would own 5% and Slate stockholders 95%. Fulcrum expects to pay a $270M cash dividend to pre-merger stockholders. The deal gives Fulcrum a new pipeline and strategic direction after months of restructuring and insider buying by 10% owner Kevin Tang. The merger likely provides a path forward for the company's $318.8M in cash, which was otherwise at risk of liquidation. Following the merger, Fulcrum Therapeutics will become Slate Medicines.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — The merger agreement values Slate at $350M and includes a $245M PIPE; pre-merger Fulcrum stockholders will own 5.0%, Slate stockholders 55.9%, and PIPE investors 39.1% of the combined company. Fulcrum expects to pay a $270M cash dividend to pre-merger stockholders.
At the time of this announcement, FULC was trading at $4.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $285.4M. The 52-week trading range was $2.83 to $15.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.